Compare Johnson & Johnson (JNJ) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KKR & Co Inc — how do they compare? Johnson & Johnson trades at $261.2 (market cap $618.09B), while KKR & Co Inc trades at $91.07 (market cap $80.39B). The key difference: Johnson & Johnson is far larger — about 7.7× KKR & Co Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and KKR & Co Inc for 67 Days on average.
| JNJ | KKR | |
|---|---|---|
Market Cap | $618.09B | $80.39B |
Volume | 6,050,983 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $278.43 | $142.75 |
52-Week Low | $186.00 | $83.88 |
Typical Hold Time | 129 Days | 67 Days |
Enterprise Value | $646.37B | $2.95B |
Dividend Yield | 2.09% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
KKR trades at $92.48, up 3.13% today, showing strong momentum after recent earnings beats. The stock faces bearish technical signals but maintains solid fundamentals with $19.21B revenue and $2.37B net income for 2025. Recent business developments include strategic joint ventures and asset sales, while analyst consensus remains overwhelmingly bullish with an average price target of $123.30.
KKR presents a compelling investment opportunity with strong earnings momentum and institutional support, though technical indicators suggest near-term caution. The company's diversified investment portfolio and active deal flow provide growth catalysts, balanced by market volatility risks and the cyclical nature of private equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
